A Study of FB1003 in Healthy and Osteoarthritis Pain Subjects
A legfontosabb adatok
- Ki végzi
- 4B Technologies Limited
- Hol
- Ausztrália2 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Toboroz
- Fázis
- 1. fázis
- Résztvevők
- 64 fő, tervezett
- Kezdés
- 2024. ápr. 7.
- Tervezett befejezés
- 2026. máj. 30.
- A vizsgálat típusa
- Beavatkozással járó, 8 csoport
- A vizsgált kezelések
- FB1003
- Placebo
- A regiszteradat frissítve
- 2025. június 15.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for healthy adults (Part 1) and adults with knee osteoarthritis pain (Part 2) to test FB1003, given as an injection under the skin.
- Életkor
- The criteria say 18 to 55 years. The record's age limits say 18 to 75 years.
- Nem
- Men and women can join.
- A betegség stádiuma
- Part 1: healthy people. Part 2: knee osteoarthritis confirmed on knee X-rays, Kellgren and Lawrence Grade ≥2, with moderate to severe pain (WOMAC pain score of ≥4).
- Korábbi kezelés
- No NSAID painkillers for 1 week before and 2 weeks after the study drug. Part 2: stop all pain medicine before Day 1 and take only the allowed paracetamol (maximum 4000 mg per day). No other study drug within 30 days or 5 half-lives.
- Biomarker vagy leletérték
- Weight at least 45 kg (99 lb) and body mass index between 18 and 32 kg/m2.
A részvétel fő kizáró okai
- Part 1: any bone or joint disease, joint surgery or joint injury.
- Part 2: kidney problems, other types of arthritis, or knee, hip or shoulder injury or surgery in the last year.
- HIV, hepatitis B or hepatitis C.
- Pregnant or breast-feeding women.
- Cancer within 5 years, serious mental illness, or nerve damage (neuropathy).
A regiszter feltételei, szó szerint
Mind a 35 feltétel megnézéseKevesebb
Ki vehet részt
- Male or female subjects who, at the time of signing the informed consent form (ICF), are between 18 and 55 years of age (inclusive)
- The subject is capable of understanding and complying with protocol requirements
- Subjects in good health based on pre-study medical history, physical examinations, vital signs, abdominal ultrasound, 12-lead ECGs, clinical laboratory tests
- Be willing to refrain from taking NSAID medications for 1 week prior to receiving study intervention and for 2 weeks after study intervention administration
- The subject weighs at least 45 kg and has a body mass index between 18 and 32 kg/m2 (inclusive)
- Must be capable of giving signed informed consent as described which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
- Women not of childbearing potential. OR must agree to use a double barrier highly effective method of contraception from the beginning of screening until at least 90 days after the last dose of study intervention; DISEASE CONDITIONS (PART 2 ONLY)
- Subject has confirmation of OA of the knee through the radiographs of both knees with a Posterior-Anterior, Fixed-flexion view taken during the Screening Period using American College of Rheumatology (ACR) clinical and radiographic diagnostic criteria
- Evidence of knee OA with a Kellgren and Lawrence (KL) Grade ≥2
- Subject is willing to discontinue all pain medication at least 5 half-lives from Day 1 visit and agree to take only the allowed Rescue Medications through study completion (maximum 4000 mg paracetamol per day)
- Subject has moderate to severe pain in the index joint defined as a Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) average pain subscale score of ≥4 at both the screening and randomization visits
Ki nem vehet részt
- Medical conditions for Part 1 only:; History or presence at the screening visit of bone or joint disorders including but not limited to OA, avascular necrosis, destructive arthropathy, pathologic fractures, osteonecrosis, rheumatoid arthritis, neuropathic joint arthropathy, lupus erythematosus, or inflammatory joint diseases; History of joint-related events such as, but not limited to, total joint replacement surgery, patella dislocation, hip dislocation, knee dislocation, or joint infections; Trauma to any joint in the 30 days prior to the screening visit
- History of myocardial infarction, acute coronary syndromes, or cerebrovascular accident within 12 months prior to the screening visit
- History or presence of malignancy within 5 years prior to screening, except subjects who have been treated successfully with no recurrence of basal or squamous cell carcinoma of the skin (<1 year), in situ cervical cancer, or in situ ductal breast cancer
- Subject has donated or lost 400 mL or more of his or her blood volume (including plasmapheresis) or had a transfusion of any blood product within 30 days prior to first dose of study intervention
- Clinically significant illness within seven days before the first dose of the study intervention
- Significant concomitant illness or any medical or surgical condition, such as, but not limited to, cardiac, renal, neurological, endocrinological, gastrointestinal, hepatic, metabolic or lymphatic disease that would adversely affect the subject's participation in this study or interpretation of safety/PK data
- Dosing with another investigational drug or therapy within 30 days or at least 5 half-lives of the investigational drug, whichever is longer
- Systolic blood pressure (SBP) >140 mmHg and/or diastolic blood pressure (DBP) >90 mmHg after 5 minutes of resting in a seated position, unless determined by the Investigator to be not clinically relevant and well controlled with medications
- Consume more than 14 (female) or 21 (male) units of alcohol per week (unit: 1 glass of wine (125 mL) = 1 measure of spirits = ½ pint of beer) within the 12 months before screening or positive screen for alcohol abuse
- Smoking >4 cigarettes (or an equivalent amount of any other nicotine-containing product) per day within 30 days before screening
- History or clinical evidence of drug abuse within the 12 months before screening or positive screen for drug abuse. Drug abuse is defined as compulsive, repetitive, and/or chronic use of drugs or other substances with or without problems related to their use and/or when stopping or a dose reduction will lead to withdrawal symptoms
- Have received a live and/or non-live vaccine (including COVID) within 28 days prior to dosing or intend to receive a vaccine during the study period or at least 56 days after the last dose of IP
- Active or history of serious mental illness or psychiatric disorder, including but not limited to schizophrenia, bipolar disorder, or major depressive disorder, which require current medical intervention
- History of autonomic neuropathy, or diabetic neuropathy, or evidence of autonomic neuropathy, or presence of clinically relevant peripheral neuropathy
- Resting heart rate of <50 or >100 beats per minute (not on ECG)
- History or evidence at screening of heart block
- Human immunodeficiency virus (HIV), hepatitis B, or hepatitis C positive by serological testing at the screening visit
- History of multiple drug allergies or history of allergic reaction to the monoclonal antibody
- History of severe intolerance to SC injection (minor reactions are permitted, e.g., localized swelling or redness)
- Any conditions which would make the subject unsuitable for enrollment or could interfere with the subject's participation in or completion of the study in the opinion of the Investigator
- Medical conditions for Part 2 only:; Clinically significant hematological findings at screening; Abnormal findings indicating renal impairment, such as creatinine ≥1.5×ULN, estimated glomerular filtration rate (eGFR) of ≤60 mL/min/1.73 m2 in adults, as calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula, at screening; A history of non-febrile seizures; History of inflammatory arthritis other than OA, in the judgment of the investigator would make the subject inappropriate for entry into this study; History of osteonecrosis / osteoporotic fracture (including minimally traumatic or atraumatic fracture); History of significant trauma (including sports injury) or surgery to a knee, hip or shoulder within last year; Fibromyalgia, regional pain caused by lumbar / cervical compression with radiculopathy, or other moderate/severe pain that may confound assessment of knee pain; A hospital admission or major surgery within 60 days prior to screening; Planned surgery to a knee, hip, or shoulder during the study
- Subject has abnormal screening or Check-in (D-1) laboratory values that suggest a clinically significant underlying disease or subject has the following lab abnormalities: alanine transferase (ALT) and/or aspartate transaminase (AST) >1.5 upper limit of normal (ULN)
- Women of reproductive potential who have a positive serum pregnancy test result at the screening visit, or a positive urine pregnancy test result at the baseline visit (D-1), or who do not have their pregnancy test results on D-1
- Pregnant or breast-feeding women
A fő feltételek kérdésként
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 18 és 75 év között vagy?
Ez a vizsgálat jelenleg itt érhető el: Ausztrália.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
The purpose of Part 1 is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants. Blood tests will be done to examine blood exposure, concentration and half-life of FB1003 following administrations. For each participant, the study will last up to about 12 weeks for single ascending dose part, and 18 weeks for multiple ascending dose part, including screening.
A teljes eredeti leírásKevesebb
The purpose of Part 2 is to assess the safety, tolerability, PK and efficacy of SAD of SC administered FB1003 in adult subjects with osteoarthritis (OA) pain.
A vizsgálat 8 csoportja
- SAD Cohort 1A vizsgált kezelés
Participants in this cohort will receive SAD dose 1 of FB1003 or Placebo.
Kezelés: FB1003 és Placebo
- SAD Cohort 2A vizsgált kezelés
Participants in this cohort will receive SAD dose 2 of FB1003 or Placebo.
Kezelés: FB1003 és Placebo
- SAD Cohort 3A vizsgált kezelés
Participants in this cohort will receive SAD dose 3 of FB1003 or Placebo.
Kezelés: FB1003 és Placebo
- SAD Cohort 4A vizsgált kezelés
Participants in this cohort will receive SAD dose 4 of FB1003 or Placebo.
Kezelés: FB1003 és Placebo
- SAD Cohort 5A vizsgált kezelés
Participants in this cohort will receive SAD dose 5 of FB1003 or Placebo.
Kezelés: FB1003 és Placebo
- OA pain Cohort1A vizsgált kezelés
Participants in this cohort will receive OA pain dose 1 of FB1003 or Placebo.
Kezelés: FB1003 és Placebo
- OA pain Cohort 2A vizsgált kezelés
Participants in this cohort will receive OA pain dose 2 of FB1003 or Placebo.
Kezelés: FB1003 és Placebo
- OA pain Cohort 3A vizsgált kezelés
Participants in this cohort will receive OA pain dose 3 of FB1003 or Placebo.
Kezelés: FB1003 és Placebo
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Escalating Single and Multiple Doses of FB1003 in the Healthy and Osteoarthritis Pain Subjects
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Kérdések a feltételekről
- Forrás: NCT06343714: ki vehet részt
- A regiszteradat frissítve
- 2025. június 15.